⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALKS News
Alkermes Inc. plc
Form 8-K
sec.gov
ALKS
Alkermes plc Reports Second Quarter 2026 Financial Results
businesswire.com
ALKS
Substance Use Disorder Treatment Market to Reach $14.6 Billion by 2030, Driven by Growing Patient Populations and Policy Reform
globenewswire.com
IVZ
ALKS
Mentari Therapeutics Appoints Industry Veteran Greg Divis as Chief Executive Officer
prnewswire.com
AVDL
ALKS
MRK
SNY
Alkermes to Report Second Quarter Financial Results on July 28, 2026
businesswire.com
ALKS
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
businesswire.com
ALKS
Form 8-K
sec.gov
ALKS
Drug-Delivery Technology Market Report 2026
globenewswire.com
MRK
ABBV
SNY
AZN
NVS
GSK
TEVA
REGN
VRTX
ALKS
HALO
Advancements in AUD Treatment: Precision Therapies and Future Growth Projections
globenewswire.com
ADIL
ALKS
LLY
ALT
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
businesswire.com
ALKS